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Backgrouds: Much of the evidence favoring the use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing primary percutaneous coronary 
intervention (PCI) for ST-elevation myocardial infarction (STEMI) was established in the era before dual oral antiplatelet therapy (aspirin plus a 
thienopyridine). The benefits of GPIs in patients pretreated with a loading dose of thienopyridine are less clear. Thus, we conducted a meta-analysis 
of all available randomized trials to reevaluate the current role of GPIs in STEMI patients adequately pretreated with dual oral antiplatelet therapy.
Methods:  The literature was scanned by formal searches of electronic databases from January 1990 to August 2010. A total of 8 randomized 
controlled trials comparing GPIs versus control in STEMI patients undergoing primary PCI who were pretreated with thienopyridines (a loading dose 
of ticlopidine 500 mg, clopidogrel 300-600 mg or prasugrel 60mg) were included, involving 8198 patients (4183 in the GPIs group, 4015 in the 
control group).
Results:  As compared to the placebo, GPIs did not reduce the endpoints of short-term (30 days) mortality (2.7% for GPIs versus 2.4% for control, 
odds ratios [OR] 1.13, 95% confidence intervals [CI] 0.86-1.48, P = 0.40), mid-term (6-12 months) mortality (4.6% vs. 4.0%, OR 1.17, 95% CI 0.95-
1.46, P = 0.15), short-term reinfarction (1.5% vs 1.7%; OR 0.90, 95% CI 0.64-1.27; P = 0.55), or mid-term reinfarction (3.3% vs. 2.9%; OR 1.15, 
95% CI 0.89 to 1.47; P = 0.29). With regard to the safety endpoints, however, both the major and minor bleeding complications in the GPIs group 
were significantly higher than those in the control group (3.8% vs. 2.3%, OR 1.60, 95% CI 1.23-2.07, P < 0.001; and 4.5% vs. 3.4%, OR 1.36, 95% CI 
1.08-1.70, P = 0.008; respectively). There was no evidence of heterogeneity in the analyses.
Conclusion: In STEMI patients scheduled for primary PCI who has been pretreated with a loading dose of thienopyridine, the additional use of GPIs 
does not provide any beneficial effect on the short- or mid-term clinical outcomes, but significantly increases the risk of bleeding.
